PMID- 19657453
OWN - NLM
STAT- MEDLINE
DCOM- 20091014
LR  - 20211020
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2009
DP  - 2009
TI  - Pinellia ternata, Citrus reticulata, and their combinational prescription inhibit 
      eosinophil infiltration and airway hyperresponsiveness by suppressing CCR3+ and 
      Th2 cytokines production in the ovalbumin-induced asthma model.
PG  - 413270
LID - 10.1155/2009/413270 [doi]
LID - 413270
AB  - BACKGROUND AND OBJECTIVE: This study was aimed to analyse the curative effects of 
      Pinellia ternata, Citrus reticulata, and their combination on airway 
      hyperresponsiveness (AHR) to inhaled methacholine, pulmonary eosinophilic 
      infiltration, Th2 cytokine production, and IgE and histamine production in a 
      murine model of asthma. METHODS: For this purpose, BALB/c mice were systemically 
      sensitized to ovalbumin (OVA) followed intratracheally, intraperitoneally, and by 
      aerosol allergen challenges for 12 weeks. We examined the development of 
      pulmonary eosinophilic accumulation, control of Th2 cytokine, immunoglobulin E 
      (IgE), and histamine productions in a murine model of asthma. RESULTS: Our data 
      suggest that the therapeutic mechanism by which Pinellia ternata, Citrus 
      reticulata, and their combinational prescription effectively treats asthma is 
      based on reductions of eosinophil infiltration, eotaxin receptor (CCR3), 
      histamine, OVA-specific IgE productions in serum, and Th2 cytokines (IL-5, IL-13) 
      by marked reductions of IL-5 and IL-13 mRNA expression in lung tissue. 
      CONCLUSIONS: These findings provide evidence that Pinellia ternata, Citrus 
      reticulata, and their combination play a regulatory role in allergic inflammation 
      and offer therapeutic approaches as novel CCR3 antagonists for treatment asthma. 
      However, it is not clear whether pharmacological activities of prescription 
      composed of two herbs are potentiated due to synergistic effect or additive 
      effect.
FAU - Ok, In-Soo
AU  - Ok IS
AD  - Department of Herbology, College of Oriental Medicine, Sangji University, Wonju 
      220-702, South Korea.
FAU - Kim, Seung-Hyung
AU  - Kim SH
FAU - Kim, Bok-Kyu
AU  - Kim BK
FAU - Lee, Jang-Cheon
AU  - Lee JC
FAU - Lee, Young-Cheol
AU  - Lee YC
LA  - eng
PT  - Journal Article
DEP - 20090802
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Ccr3 protein, mouse)
RN  - 0 (Interleukin-13)
RN  - 0 (Interleukin-5)
RN  - 0 (Plant Extracts)
RN  - 0 (Receptors, CCR3)
RN  - 207137-56-2 (Interleukin-4)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/pharmacology/therapeutic use
MH  - *Asthma/chemically induced/drug therapy/immunology
MH  - Bronchial Hyperreactivity/drug therapy/immunology
MH  - Cells, Cultured
MH  - Citrus/*chemistry
MH  - Disease Models, Animal
MH  - Drug Therapy, Combination
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Immunohistochemistry
MH  - Interleukin-13/immunology/metabolism
MH  - Interleukin-4/immunology/metabolism
MH  - Interleukin-5/immunology/metabolism
MH  - Lung/drug effects/immunology/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - *Ovalbumin
MH  - Pinellia/*chemistry
MH  - Plant Extracts/*pharmacology/therapeutic use
MH  - Polymerase Chain Reaction
MH  - Receptors, CCR3/*immunology
MH  - Th2 Cells/drug effects/*immunology
PMC - PMC2719786
EDAT- 2009/08/07 09:00
MHDA- 2009/10/15 06:00
PMCR- 2009/08/02
CRDT- 2009/08/07 09:00
PHST- 2009/01/20 00:00 [received]
PHST- 2009/03/23 00:00 [revised]
PHST- 2009/05/22 00:00 [accepted]
PHST- 2009/08/07 09:00 [entrez]
PHST- 2009/08/07 09:00 [pubmed]
PHST- 2009/10/15 06:00 [medline]
PHST- 2009/08/02 00:00 [pmc-release]
AID - 10.1155/2009/413270 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2009;2009:413270. doi: 10.1155/2009/413270. Epub 2009 Aug 2.